News >

PD-1 Inhibition Reigns Supreme in Frontline Advanced RCC

Caroline Seymour
Published: Tuesday, Mar 31, 2020

Dr. Mario Sznol

Mario Sznol, MD
The role of immunotherapy in metastatic renal cell carcinoma (mRCC) has grown tremendously with dual immune checkpoint inhibition and combinations of anti–PD-1/VEGF inhibitors, explained Mario Sznol, MD, in a presentation during the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication